Kennedy Capital Management LLC Grows Stake in LivaNova PLC (NASDAQ:LIVN)

Kennedy Capital Management LLC boosted its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 285,708 shares of the company's stock after purchasing an additional 24,068 shares during the quarter. Kennedy Capital Management LLC owned about 0.53% of LivaNova worth $13,231,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in LIVN. Vanguard Group Inc. raised its stake in LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after buying an additional 265,291 shares during the last quarter. Geode Capital Management LLC raised its position in shares of LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock worth $70,676,000 after purchasing an additional 8,331 shares during the last quarter. Emerald Advisers LLC boosted its stake in LivaNova by 8.2% in the 4th quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock worth $34,850,000 after purchasing an additional 57,035 shares in the last quarter. Paradice Investment Management LLC grew its position in LivaNova by 15.3% during the 4th quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after purchasing an additional 64,680 shares during the last quarter. Finally, Artisan Partners Limited Partnership bought a new stake in LivaNova during the 4th quarter valued at about $21,340,000. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Mizuho cut their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. StockNews.com raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Needham & Company LLC reissued a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research report on Monday, March 17th. Finally, Stifel Nicolaus dropped their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $61.17.

LivaNova Stock Performance

LIVN traded down $0.51 during trading on Tuesday, hitting $34.95. The company's stock had a trading volume of 227,811 shares, compared to its average volume of 625,399. LivaNova PLC has a one year low of $32.48 and a one year high of $64.48. The business's 50 day simple moving average is $41.10 and its 200-day simple moving average is $47.17. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market cap of $1.90 billion, a PE ratio of 83.21 and a beta of 0.90.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.